Cipla Uncorks Peptide Injectables Pipeline
Indian Giant Also Eyes Partnering Opportunities For Monkeypox
Executive Summary
Cipla readies scale-up in peptide injectables with five filings in the US and gears for upcoming high-value launches for generic versions of Advair, Revlimid and Abraxane. The company is also exploring partnering opportunities for monkeypox.
You may also be interested in...
Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside
Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.
EMA To Track Monkeypox Medicines Stock & Boost Emergency Task Force Output
The European Medicines Agency is taking more actions to tackle monkeypox now that the disease has been declared a public health emergency.
Cipla Lines Up Advair But Costs Will Flatten High-Value Launches
A generic version of Advair is high on Cipla’s plans for its current financial year ending in March 2023. Management discussed the high-value respiratory asset and the company’s further prospects during the Indian firm’s annual earnings call, which included the company passing $1bn in sales for its domestic branded prescription business.